NASDAQ$OMER

Omeros Corp · Q4 2023 earnings

Q4 2023 earnings · · Investor relations

Briefing

Reported financial results for the fourth quarter and year ended December 31, 2023.

Omeros Corporation reported a net loss of $9.1 million for Q4 2023, compared to a net loss of $37.8 million for the third quarter of 2023. The company's cash used in operations for the fourth quarter was $34.8 million. They received $115.5 million from DRI in February 2024.

  • Net loss for the fourth quarter of 2023 was $9.1 million, or $0.15 per share.
  • Omeros and DRI Healthcare Acquisitions LP amended the OMIDRIA royalty purchase agreement, resulting in Omeros receiving $115.5 million in cash.
  • At December 31, 2023, Omeros had $171.8 million of cash and short-term investments available.
  • Omeros continues to engage with FDA regarding the planned resubmission of its Biologics License Application for narsoplimab in hematopoietic stem cell transplant-associated thrombotic microangiopathy.

Headline financials

Total Revenue

$1.37M

No prior period
EPS (adj)

-$0.63

Previous: -$0.73+13.7%
Capital Expenditures

$118K

Previous: $13K+807.7%
Net Income

-$9.1M

Previous: $129M-107.1%
Operating Income

-$39.8M

Previous: -$40.1M+0.9%
Gross Profit

$0.00

No prior period
R&D Expense

$28.9M

No prior period
Stock-Based Comp

$2.69M

Previous: $3.26M-17.6%

Revenue & EPS history

Omeros · Revenue · Quarterly

$1.37M

Q4 2023
Beat estimate in 0 of 5 quarters(0%)
ActualEstimate

Revenue by segment

Omeros · $31.9M total across 1 segment · Q4 2021

  • OMIDRIA royalties
    $31.9M

Forward guidance

Omeros expects its first quarter net loss to be $34.0 to $37.0 million or $0.58 to $0.63 loss per share. As of March 31, 2024, we expect our cash and investments balance available for operations and debt service to be approximately $230.0 million after repurchasing 3.2 million shares of our outstanding common stock for $11.9 million during the first quarter.

Historical earnings impact

How earnings announcements have historically affected this stock's price.

Avg. return before/after earnings

Based on 18 quarterly earnings reports · overlaid with Q4 2023

Historical avgQ4 2023

+2.4%

Avg return

Earnings day

+4.6%

Avg return

5 days after

+7.1%

Avg return

30 days after

43%

28 / 65 earnings

Positive

+64.2%

Q4 2019

Best reaction

-21.2%

Q1 2024

Worst reaction

Earnings price reactions
QuarterReport dateReaction (Day 0)+5 days+30 days
Q4 2025+7.5%-7.1%
Q1 2026-2.5%-20.8%-40.9%
Q3 2025+26.3%+30.9%+61.6%
Q2 2025+7.0%+1.7%+0.7%
Q1 2025-18.7%-21.3%-13.9%
Q4 2024-3.8%-14.1%-14.6%
Q3 2024+63.1%+39.0%+79.1%
Q2 2024-10.5%-2.1%-16.7%
Q1 2024-21.2%-21.4%-3.3%
Q4 2023-11.6%-0.6%-1.4%
Q3 2023-3.8%+14.6%+97.7%
Q2 2023-1.2%-6.1%-20.7%
Q1 2023+21.2%+14.2%+51.4%
Q4 2022+15.6%+8.6%+72.1%
Q3 2022-16.9%-10.9%-35.6%
Q2 2022+10.5%+5.6%-19.4%
Q1 2022-5.4%+15.9%-22.5%
Q4 2021-5.1%-11.2%-16.5%
Q3 2021+7.6%+10.1%+6.3%
Q2 2021+1.5%+4.4%+5.3%
Q1 2021+3.8%+2.5%-9.6%
Q4 2020+1.2%-7.3%-10.7%
Q3 2020+6.1%+11.3%+37.0%
Q2 2020+12.5%-4.0%-22.2%
Q1 2020-6.2%-12.0%-2.2%
Q4 2019+64.2%+51.8%+8.7%
Q3 2019+2.2%-3.9%-3.9%
Q2 2019+14.7%+20.6%+14.4%
Q1 2019+5.1%+0.9%-8.3%
Q4 2018+12.5%+9.2%+20.5%
Q3 2018-20.3%-22.2%-14.2%
Q2 2018-18.0%-4.7%+16.9%
Q1 2018+18.0%+45.0%+8.7%
Q4 2017-0.9%-0.1%+10.6%
Q3 2017+27.5%+33.1%+37.5%
Q2 2017+12.4%+5.9%-6.8%
Q1 2017-7.7%-6.4%-4.7%
Q4 2016-7.9%-2.9%+34.7%
Q3 2016+28.7%+45.8%+9.4%
Q2 2016+3.0%-7.9%-8.9%
Q1 2016-15.0%
Q4 2015+24.7%
Q3 2015-1.3%
Q2 2015-3.1%
Q1 2015+4.8%
Q4 2014-6.2%
Q3 2014+9.7%
Q2 2014-5.7%
Q1 2014-6.9%
Q4 2013-11.7%
Q3 2013-5.6%
Q2 2013-7.2%
Q1 2013+17.5%
Q4 2012-3.7%
Q3 2012-17.1%
Q2 2012-2.2%
Q1 2012-0.6%
Q4 2011-3.5%
Q3 2011-2.0%
Q2 2011+3.0%
Q1 2011-0.8%
Q4 2010-3.8%
Q3 2010-3.2%
Q2 2010-12.3%
Q1 2010-3.2%

Discussion

Share your read of this quarter. Sign-in carries your eToro identity.

Join the conversation

Sign in with eToro to post your read of this quarter and vote on others'.

Sign in with eToro